Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-acting erythropoietin vs roxadustat for haemoglobin target attainment in maintenance haemodialysis
ChiCTR2300078632Phase 4Not yet recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Dec 2023
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of darbepoetin alfa and roxadustat in Uraemic Anaemia and chronic kidney disease (CKD) (2 arms), sponsored by Shenzhen Second People's Hospital. Primary endpoint: Mean haemoglobin maintained at 10–12 g/dL at 12–16 weeks. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
darbepoetin alfaroxadustat
03
Conditions
Uraemic Anaemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2300078632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078632.